- Home
- WENC vs IMUX Comparison
WENC vs IMUX Comparison
Compare WENC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WENC | IMUX |
|---|---|---|
| Founded | 2025 | 2016 |
| Country | Mexico | United States |
| Employees | N/A | 66 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 155.8M |
| IPO Year | 2026 | 2013 |
Fundamental Metrics
Financial Performance| Metric | WENC | IMUX |
|---|---|---|
| Price | $10.02 | $6.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | 13.9K | ★ 392.9K |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $166.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $0.51 |
| 52 Week High | $10.05 | $17.43 |
Technical Indicators
Market Signals| Indicator | WENC | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 24.48 |
| Support Level | $9.99 | $0.83 |
| Resistance Level | N/A | $15.82 |
| Average True Range (ATR) | 0.01 | 0.63 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 41.67 | 0.17 |
Price Performance
Historical ComparisonAbout WENC West Enclave Merger Corp. Ordinary Shares
West Enclave Merger Corp is a blank check company.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.